
Danish pharmaceutical giant Novo Nordisk posted bumper profits for 2023 on Wednesday, driven by blockbuster sales of diabetes and obesity treatments that helped it become Europe's most valuable company.
The century-old company has also turned into a major driver of Denmark's economy as sales of diabeties medication Ozempic and obesity drug Wegovy have boomed.